| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,480 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
500,000 |
525,000 |
525,000 |
525,000 |
| Total Buy Value |
$324,050 |
$343,050 |
$343,050 |
$343,050 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Armen Garo H |
Chairman & CEO |
• – – |
2012-10-26 |
4 |
A |
$4.42 |
$6,135 |
D/D |
1,388 |
657,004 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-10-01 |
4 |
A |
$4.73 |
$13,197 |
D/D |
2,790 |
655,616 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2012-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
1,660 |
22,856 |
|
- |
|
| Sharp Shalini |
Director |
– • – |
2012-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
4,035 |
80,637 |
|
- |
|
| Wentworth Kerry |
VP Clinical, Reg & Quality |
• – – |
2012-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
5,044 |
36,021 |
|
- |
|
| Valentine Karen |
VP General Counsel |
• – – |
2012-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,410 |
28,550 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
11,126 |
652,826 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-09-04 |
4 |
A |
$4.64 |
$13,200 |
D/D |
2,845 |
641,700 |
|
- |
|
| Sharp Shalini |
Director |
– • – |
2012-08-29 |
4 |
AS |
$4.64 |
$1,336 |
D/D |
(288) |
76,602 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-08-01 |
4 |
A |
$5.08 |
$13,196 |
D/D |
2,600 |
638,855 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-07-27 |
4 |
A |
$4.55 |
$326,908 |
D/D |
71,848 |
636,255 |
|
- |
|
| Wentworth Kerry |
VP, Clinical, Req & Quality |
• – – |
2012-07-26 |
4 |
A |
$4.61 |
$3,199 |
D/D |
694 |
30,977 |
|
- |
|
| Valentine Karen |
VP, General Counsel |
• – – |
2012-07-26 |
4 |
A |
$4.61 |
$1,918 |
D/D |
416 |
26,140 |
|
- |
|
| Sharp Shalini |
Director |
– • – |
2012-07-26 |
4 |
A |
$4.61 |
$2,881 |
D/D |
625 |
76,890 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-07-26 |
4 |
A |
$4.61 |
$6,403 |
D/D |
1,389 |
564,407 |
|
- |
|
| Klaskin Christine M |
VP, Finance |
• – – |
2012-07-26 |
4 |
A |
$4.61 |
$1,918 |
D/D |
416 |
21,196 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-07-02 |
4 |
A |
$5.27 |
$13,198 |
D/D |
2,505 |
563,018 |
|
- |
|
| Wentworth Kerry |
VP, Clinical, Reg, & Quality |
• – – |
2012-06-21 |
4 |
D |
$5.05 |
$74,659 |
D/D |
(14,784) |
30,283 |
|
- |
|
| Sharp Shalini |
Director |
– • – |
2012-06-21 |
4 |
D |
$5.05 |
$20,740 |
D/D |
(4,107) |
76,265 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2012-06-21 |
4 |
D |
$5.05 |
$19,241 |
D/D |
(3,810) |
20,780 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-06-21 |
4 |
D |
$5.05 |
$147,440 |
D/D |
(29,196) |
560,513 |
|
- |
|
| Wentworth Kerry |
VP, Clinical, Reg, & Quality |
• – – |
2012-06-20 |
4 |
D |
$4.99 |
$70,613 |
D/D |
(14,151) |
45,067 |
|
- |
|
| Sharp Shalini |
Director |
– • – |
2012-06-20 |
4 |
D |
$4.92 |
$10,913 |
D/D |
(2,218) |
80,372 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2012-06-20 |
4 |
D |
$4.99 |
$18,194 |
D/D |
(3,646) |
24,590 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2012-06-20 |
4 |
D |
$4.92 |
$77,702 |
D/D |
(15,793) |
589,709 |
|
- |
|
534 Records found
|
|
Page 10 of 22 |
|
|
